妇科肿瘤患者中芳香化酶抑制剂的使用、副作用及停药率
该回顾性研究分析了146例接受芳香化酶抑制剂(AI)治疗的妇科肿瘤患者,其中卵巢癌68例(46.6%)、子宫癌78例(53.4%)。54.1%在开始AI治疗后前三次就诊内出现副作用,最常见为关节痛(29.5%)。停药主因是疾病进展(87.9%),仅5.0%因副作用停药。
要点
- 146例妇科肿瘤患者中,54.1%在AI治疗开始后前三次就诊内出现副作用。
- 最常见副作用为关节痛(29.5%)、潮热(25.3%)和新发/加重乏力(16.4%)。
- 停药主因为疾病进展(87.9%),因副作用停药仅5.0%。
核心结论
- 妇科肿瘤的AI治疗常伴肌肉骨骼副作用,但很少导致治疗中断。
- 作者认为应评估妇科肿瘤患者的AI副作用,以便通过辅助治疗潜在缓解症状。
研究设计与样本
- 回顾性研究,从电子病历中提取因妇科癌症接受AI治疗的子宫和卵巢癌患者数据。
- 共纳入146例女性,其中卵巢癌68例(46.6%)、子宫癌78例(53.4%)。
- 71.9%在诊断时为晚期疾病。
主要发现
- 54.1%在开始AI治疗后前三次就诊内出现AI相关副作用。
- 最常见副作用为关节痛(29.5%)、潮热(25.3%)、新发/加重乏力(16.4%)、肌肉或关节僵硬(8.2%)和肌痛(6.8%)。
- 平均治疗持续时间为14.7个月。
- 加巴喷丁使用与肌肉骨骼副作用减少相关(p < .001,OR 0.88,95% CI 0.83-0.94)。
- 选择性5-羟色胺再摄取抑制剂(SSRI)使用与肌肉骨骼副作用减少相关(p < .001,OR 0.82,95% CI 0.77-0.89)。
关键数值与推荐
- 停药最常见原因为疾病进展(87.9%),5.0%因副作用停药,7.1%因其他原因停药。
临床怎么用
- 作者认为应评估妇科肿瘤患者的AI副作用,以便通过辅助治疗潜在缓解症状。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Aromatase inhibitors (AI) are frequently prescribed in gynecologic oncology. We sought to define the frequency and duration of AI use, characterize AI side effects and determine the reasons for discontinuation in these patients. METHODS: Uterine and ovarian cancer patients with AI use for gynecologic cancer therapy were identified retrospectively. Data were abstracted from the electronic medical record, including cancer type, stage, prior cancer treatments, body mass index, concurrent medications, prevalence of AI side effects before and during AI therapy, length of AI treatment and reason for AI discontinuation. RESULTS: 146 women received AI therapy, with 68 for ovarian cancer (46.6%) and 78 for uterine cancer (53.4%). The majority (71.9%) had advanced stage disease at diagnosis. 54.1% noted AI-associated side effects within the first three visits after starting AI therapy. The most common side effects were arthralgias (29.5%), hot flashes (25.3%), new/worsening fatigue (16.4%), muscle or joint stiffness (8.2%) and myalgias (6.8%). The mean duration of therapy was 14.7 months. Gabapentin or selective serotonin reuptake inhibitor (SSRI) use was associated with decreased musculoskeletal side effects (gabapentin: p < .001, OR 0.88, 95% CI 0.83-0.94; SSRI: p < .001, OR 0.82, 95% CI 0.77-0.89). The most common reason for AI discontinuation was disease progression (87.9%), with 5.0% discontinuing due to side effects and 7.1% for other reasons. CONCLUSION: AI therapy for gynecologic cancers is frequently associated with musculoskeletal side effects, but rarely leads to treatment discontinuation. Thus, AI side effects should be assessed in gynecologic cancer patients to allow potential mitigation of symptoms through adjunct therapies.
引用
- Bell SG, Dalton L, McNeish BL, et al. Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients. Gynecol Oncol. 2020. PMID: 32847676. doi:10.1016/j.ygyno.2020.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。